Profile Response Detail

Molecular Profile Unknown unknown
Therapy Carboplatin + Paclitaxel + Panobinostat
Indication/Tumor Type Advanced Solid Tumor
Response Type not applicable
Create By cms
Update By smockus


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Carboplatin + Paclitaxel + Panobinostat Phase I Actionable In a Phase I trial, 52% (11/21) of patients with advanced solid tumors demonstrated stable disease when treated with Farydak (panobinostat), in combination with Paraplatin (carboplatin) and Taxol (paclitaxel) (PMID: 22851205). 22851205
PubMed Id Reference Title Details
(22851205) A phase I trial of oral administration of panobinostat in combination with paclitaxel and carboplatin in patients with solid tumors. Full reference...